1. Home
  2. MNMD

as of 12-29-2025 12:17pm EST

$13.41
+$0.35
+2.68%
Stocks Health Care Pharmaceuticals and Biotechnology Nasdaq

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

Founded: 2019 Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 1.3B IPO Year: N/A
Target Price: $30.33 AVG Volume (30 days): 2.0M
Analyst Decision: Strong Buy Number of Analysts: 9
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.98 EPS Growth: N/A
52 Week Low/High: $4.70 - $14.43 Next Earning Date: 11-06-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

AI-Powered MNMD Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 18 hours ago

AI Recommendation

hold
Model Accuracy: 73.08%
73.08%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Mind Medicine (MindMed) Inc. News

MNMD Breaking Stock News: Dive into MNMD Ticker-Specific Updates for Smart Investing

All MNMD News

Share on Social Networks: